Impact of innate immunity in a subset of children with autism spectrum disorders: a case control study by Jyonouchi, Harumi et al.
BioMed  Central
Page 1 of 14
(page number not for citation purposes)
Journal of Neuroinflammation
Open Access Research
Impact of innate immunity in a subset of children with autism 
spectrum disorders: a case control study
Harumi Jyonouchi*1, Lee Geng1, Agnes Cushing-Ruby1 and Huma Quraishi2
Address: 1Division of Allergy/Immunology and Infectious Diseases, Department of Pediatrics, University of Medicine and Dentistry of New Jersey 
(UMDNJ)-New Jersey Medical School (NJMS), Newark, NJ, USA and 2Department of Surgery, University of Medicine and Dentistry of New Jersey 
(UMDNJ)-New Jersey Medical School (NJMS), Newark, NJ, USA
Email: Harumi Jyonouchi* - jyanouha@umdnj.edu; Lee Geng - gengle@umdnj.edu; Agnes Cushing-Ruby - cushinag@umdnj.edu; 
Huma Quraishi - quraisha@umdnj.edu
* Corresponding author    
Abstract
Background: Among patients with autism spectrum disorders (ASD) evaluated in our clinic, there
appears to be a subset that can be clinically distinguished from other ASD children because of frequent
infections (usually viral) accompanied by worsening behavioural symptoms and/or loss/decrease in
acquired skills. This study assessed whether these clinical features of this ASD subset are associated with
atopy, asthma, food allergy (FA), primary immunodeficiency (PID), or innate immune responses important
in viral infections.
Methods: This study included the ASD children described above (ASD test, N = 26) and the following
controls: ASD controls (N = 107), non-ASD controls with FA (N = 24), non-ASD controls with chronic
rhinosinusitis/recurrent otitis media (CRS/ROM; N = 38), and normal controls (N = 43). We assessed
prevalence of atopy, asthma, FA, CRS/ROM, and PID. Innate immune responses were assessed by
measuring production of proinflammatory and counter-regulatory cytokines by peripheral blood
mononuclear cells (PBMCs) in response to agonists of Toll-like receptors (TLRs), with or without pre-
treatment of lipopolysaccharide (LPS), a TLR4 agonist.
Results: Non-IgE mediated FA was equally prevalent in both ASD test and ASD control groups, occurring
at higher frequency than in the non-ASD controls. Allergic rhinitis, atopic/non-atopic asthma, and atopic
dermatitis were equally prevalent among the study groups except for the CRS/ROM group in which non-
atopic asthma was more prevalent (52.6%). CRS/ROM and specific polysaccharide antibody deficiency
(SPAD) were more prevalent in the ASD test group than in the ASD control, FA, and normal control
groups: 23.1% vs. < 5% for CRS/ROS and 19.2% vs. < 1% for SPAD. However, CRS/ROM patients had the
highest prevalence of SPAD (34.2%). When compared to ASD and normal case controls, PBMCs from 19
non-SPAD, ASD test group children produced: 1) less IL-1β with a TLR7/8 agonist, less IL-10 with a TLR2/
6 agonist, and more IL-23 with a TLR4 agonist without LPS pre-treatment, and 2) less IL-1β with TLR4/7/
8 agonists with LPS pre-treatment. These are cytokines associated with the neuro-immune network.
Conclusion: Clinical features of the ASD test group were not associated with atopy, asthma, FA, or PID
in our study but may be associated with altered TLR responses mediating neuro-immune interactions.
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Background
Autism spectrum disorder (ASD) is a complex develop-
mental disorder encompassing a heterogeneous patient
population. It is generally agreed that there are at least two
types of ASD with regard to disease development; abnor-
mal cognitive development evident from birth (classical
autism) and developmental regression, usually between
18–24 months of age, following apparent normal devel-
opment (regressive autism) [1].
In addition to behavioral symptoms, co-morbid clinical
conditions such as gastrointestinal (GI) symptoms are fre-
quently noted in ASD children. A high prevalence of GI
symptoms, which often improve after dietary interven-
tion, has been reported by parents. This has led to specu-
lation that there may be a high prevalence of food allergy
(FA) in ASD children. Although IgE-mediated FA does not
appear to be prevalent in ASD children, our previous
study indicated a higher prevalence of non-IgE mediated
FA (NFA) in ASD children. Specifically, our results
revealed increased tumour necrosis factor-α (TNF-α) pro-
duction against cow's milk protein along with correlating
clinical features consistent with NFA [2]. In these ASD
children with NFA, we also observed excessive production
of TNF-α in response to LPS, an agonist of Toll-like recep-
tor 4 (TLR4) [3].
Apart from FA, we have also encountered a number of
ASD children who suffer from recurrent infection (typi-
cally viral syndromes) accompanied by exacerbations of
behavioral symptoms (hyperactivity, temper tantrums,
irritability and self-stimulatory behaviors) despite good
responses to dietary intervention. Such behavioral
changes were pointed out by teachers/therapists/care tak-
ers independent of parents. Immune insult via microbial
infection caused by various pathogens appears to counter-
act beneficial effects of behavioral, dietary, and other
intervention measures in these ASD children. However,
atopy or primary immunodeficiency (PID) does not
appear to be a major factor in these children. The above-
described clinical observations led us to hypothesize that
in these ASD children, antigen non-specific (innate)
immune responses are altered, leading to dysregulated
neuro-immune interactions apart from PID or atopy.
Among 133 ASD children evaluated in our clinic, we iden-
tified 26 ASD children with the above-described clinical
features (ASD test group). Interestingly, they are all docu-
mented to have shown regression at the onset of symp-
toms. In this study, we assessed prevalence of atopy, FA,
CRS/ROM, and PID in the ASD test and control groups as
well as in the non-ASD control groups (FA, CRS/ROM,
and normal controls). In addition, we assessed responses
to a panel of TLR agonists in 19 ASD test group children
and compared these to responses for ASD and normal
case controls.
Methods
Study Subjects
Study subjects included children with ASD, CRS/ROM,
and FA that were referred to the Pediatric Allergy/Immu-
nology Clinic at our institution from April, 2005 through
May, 2008. These children were evaluated for atopic dis-
orders, FA, and PID as medically indicated. They were also
enrolled in institutional review board- (IRB-) approved
study protocols that involved additional immunological
evaluation of innate/adaptive immune responses. Control
children were recruited from the same clinic and also from
the General Pediatrics Clinic, and were evaluated for
innate immune responses and atopy through their partic-
ipation in established study protocols. Control children
were children with no major medical issues affecting
major organ systems, no documented behavioural prob-
lems, and age-appropriate cognitive activity as deter-
mined by his/her primary physician's evaluations and
reported school performances obtained from chart review
and from histories taken from their parents.
Demographic data of the study subjects are summarized
in Table 1. Consistent with previous reports, the male/
female ratio is significantly high in ASD children [4]. Nor-
mal control children also included higher numbers of
males, reflecting our efforts to recruit normal control sub-
jects matching the test group ASD children in age and sex.
None of our study subjects were diagnosed with celiac dis-
ease or inflammatory bowel diseases.
ASD diagnosis
ASD diagnosis was made or ascertained by DSM-IV (Diag-
nostic and Statistical Manual of Mental Disorders IV) cri-
teria, ADI-R (Autism Diagnostic Interview-Revised), and/
or ADOS (Autism Diagnostic Observational Schedules).
ASD diagnosis was made by board-certified developmen-
tal pediatricians and/or pediatric neurologists/psychia-
trists. The ADI-R and ADOS were administered by
certified examiners from various autism centers including
the ones at our institution.
The ASD test group was defined by having 1) frequent
infections (more than 6/year documented by a physician)
with poor responses to treatment measures such as the
first line antibiotics and 2) at least 3 occurrences of
changes in behavioral symptoms and/or loss of cognitive
skills following infection, documented independently by
caretakers, teachers, and therapists. Parents of the ASD test
group reported repeated set backs of their children's
progress at home and at school due to loss of acquired
skills and interference from worsening behavioral issues.
It is of note that all the ASD test group subjects were doc-Journal of Neuroinflammation 2008, 5:52 http://www.jneuroinflammation.com/content/5/1/52
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umented to have normal growth and development that
was followed by major regression between 15–30 months
of age. In most cases, this regression followed some type
of immune insult (typically a viral syndrome.)
Diagnosis of atopic disorders
Allergic rhinitis (AR), allergic conjunctivitis (AC), and
atopic dermatitis (AD) were diagnosed with positive skin-
prick test reactivity and/or presence of allergen-specific
IgE accompanied by clinical features consistent with AR,
AC, or AD [5-7]. Asthma diagnosis was based on NIH
guideline criteria [8]. Asthma without skin test reactivity
and/or allergen-specific IgE antibody was categorized as
non-atopic asthma[5]
Diagnosis of NFA
NFA to common dietary proteins (cow's milk protein,
wheat, and soy) was diagnosed using the following crite-
ria: 1) presence of objective GI symptoms (diarrhea, loose
stool, and constipation) that resolved with avoidance of
causative DPs, 2) delayed (more than 6 h) recurrence of
GI symptoms following exposure to offending food after
resolution of GI symptoms, and 3) cellular immune reac-
tivity to offending dietary proteins defined as production
of TNF-α and/or IL-12 greater than 1 standard deviation
above control mean value by PBMCs after stimulation
with causative dietary proteins [2].
Evaluation of ROM and CRS
ROM was defined as physician-diagnosed OM occurring
more than 6 times/year. Most of the ROM patients
referred to our clinic were unresponsive to surgical inter-
ventions (installment of pressure-equalizing tube and
tonsillectomy/adenoidectomy). CRS was diagnosed with
documentation of sinus inflammation by imaging studies
(computerized tomography) despite prior prolonged/
repeated courses of antibiotic therapy (more than 12
weeks) [9].
Evaluation of primary immunodeficiency
Presence of PID was evaluated in those patients with clin-
ical features suggesting immune abnormalities such as
recurrent or prolonged infections unresponsive to con-
ventional treatment. Our routine immunological workup
includes the following: serum levels of immunoglobulin
(Ig), IgG subclass, and antibody titers to recall antigens;
enumeration of peripheral blood T and B cell subsets, and
T cell responses to mitogens and recall antigens.
For evaluation of innate immune responses, blood sam-
ples were collected following obtainment of the IRB-
approved signed consent forms. At the time of venipunc-
ture, all the study subjects were afebrile, were not on anti-
biotics, and had no evidence of acute microbial illnesses
by physical examination.
Cell cultures
PBMCs were isolated by Ficoll-Hypaque density gradient
centrifugation. Innate immune responses were assessed
by incubating PBMCs (106 cells/ml) overnight with TLR4
agonist (LPS; 0.1 μg/ml, GIBCO-BRL, Gaithersburg, MD),
TLR2/6 agonist (zymosan; 50 μg/ml, Sigma-Aldrich, St.
Luis, Mo), and TLR7/8 agonist (CL097, water-soluble
derivative of imidazoquinoline, 20 μM, InvivoGen, San
Diego, CA) in RPMI 1640 with additives as described
before [10]. We then measured the levels of proinflamma-
tory (TNF-α, IL-1β, IL-6, IL-12p40, IL-23) and counter-
regulatory (IL-10, sTNFRII, and TGF-β) cytokines in the
culture supernatant. When testing the effects of LPS pre-
treatment, PBMCs were incubated overnight with LPS (0.1
μg/ml), the medium replaced, and then re-stimulated
with the above-described TLR agonists.
Table 1: Demographics of the study subjects
Study Group Number Age (yr) Median (range) Sex (male: female) Race
ASD1
Test 26 7.6 (2.3–13.4) 25:1 W2 24, H 1, AA 0, A 1
Control 107 4.8 (1.5–17.3) 92:15 W 77, H 7, AA 11, A 9, other 3
CRS/ROM 38 6.8 (1.0–17.8) 27:11 W 12, H 16, AA 8, A 2
FA 24 2.5 (1.0–13.7) 18:6 W 12, H 4, AA 4, A 4
Control 43 7.0 (1.0–13.8) 31:12 W 31, H 6, AA 3, A 3
1 ASD test group patients were diagnosed with autism (N = 21), pervasive developmental disorder not otherwise specified (PDD-NOS) (N = 4), 
and ASD (not categorized as autism or PDD-NOS due to age) (N = 1). ASD control group patients were diagnosed with autism (N = 70), PDD-
NOS (N = 27), and ASD (not categorized as autism or PDD-NOS due to age) (N = 10).
2 Abbreviations: W Caucasian, H Hispanic, AA African American, A Asian.Journal of Neuroinflammation 2008, 5:52 http://www.jneuroinflammation.com/content/5/1/52
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All cytokine levels were measured by an enzyme-linked
immunosorbent assay, using OptEIA™ Reagent Sets (BD
Pharmingen, San Diego, CA) for TNF-α, IL-1β, IL-6, IL-10,
IL-12p40 and ELISA reagent set (R & D, Minneapolis,
MN) for sTNFRII and TGF-β. IL-23 ELISA kit was pur-
chased from eBioscience (San Diego, CA). Intra- and
inter-variations of cytokine levels were less than 5%.
Statistics
For comparison of test values with control values, a Wil-
coxon signed rank test was used. For comparison of values
of multiple groups, a Kruskall-Walls test was used. For
case control studies, a paired Wilcoxon signed rank test
was used. Assessment of difference of frequency was tested
with a Chi square (χ2) test. These tests were performed
using R.2.5.1 (R-Development Core Team 2007). A p
value of < 0.05 was considered to be statistically signifi-
cant.
Results
Prevalence of atopy, FA, CRS/ROM, and PID in the study 
subjects
Table 2 summarizes the prevalence of atopy, FA, CRS/
ROM, and PID in all of the study groups.
Despite the fact that many parents of ASD children
reported that their children suffered from 'allergies', the
prevalence of atopic disorders (AR+AC, AD, and atopic
asthma) in the ASD test and ASD control groups were sim-
ilar to that of the general population and to our normal
controls [11]. CRS is a major trigger for asthma [12] and,
not surprisingly, CRS/ROM patients were distinguished
by a high frequency of atopic and non-atopic asthma as
compared to other study groups (Table 2). In FA children,
prevalence of atopy was not high but this may reflect their
young age. AR+AC, AD, and asthma frequency in control
children were equivalent to that in the general population
[11]. These results indicate that atopy is not closely asso-
ciated with clinical features of the ASD test group.
Consistent with the high prevalence of GI symptoms in
ASD children, non-IgE-mediated, but not IgE-mediated,
FA was observed at a high frequency in both ASD test and
ASD control groups (Table 2). In contrast, despite fre-
quent antibiosis, which causes GI symptoms by disrupt-
ing commensal flora and may subsequently predispose
the subjects to FA, NFA was not as prevalent in CRS/ROM
children as in the ASD children (p = 4.048e-11 by χ2 test)
(Table 2). These results indicate that FA is not closely asso-
ciated with the clinical characteristics of the ASD test
group.
The ASD test group children showed higher frequency of
CRS/ROM and PID than did the ASD control group (Table
Table 2: Prevalence of atopy, food allergy, CRS/ROM and primary immunodeficiency in study subjects
Group AR+AC Asthma AD FA CRS & ROM PID2
Atopy+ Atopy - IgE non-IgE
ASD1
Test3 7/26
(26.9%)
2/26
(7.7%)
2/26
(7.7%)
1/26
(3.8%)
2/26
(7.7%)
23/26
(88.5%)
6/265
(23.1%)
5/26
(19.2%)
Control 23/107
(21.5%)
4/107
(2.4%)
11/107
(10.3%)
6/107
(5.6%)
6/107
(5.6%)4
82/107
(76.6%)
5/107
(4.7%)
1/107
(0.9%)
CRS & ROM 9/38
(23.7%)
9/386
(23.7%)
20/386
(52.6%)
0 0 7/38
(18.4%)
38/38
(100%)
13/38
(34.2%)
FA 5/24
(20.8%)
2/24
(8.3%)
2/24
(8.3%)
2/24
(8.3%)
3/24
(12.5%)
22/24
(91.7%)
1/24
(4.3%)
1/242
(4.3%)
Control7 8/43
(18.6%)
6/43
(14.0%)
2/43
(4.7%)
2/43
(4.7%)
000 0
1 Abbreviations: AC allergic conjunctivitis, AD atopic dermatitis, AR allergic rhinitis, ASD autism spectrum disorders, CRS chronic rhinosinusitis, FA 
food allergy, PID primary immunodeficiency, ROM recurrent otitis media.
2 PID; ASD test/control groups: all diagnosed as specific Ab deficiency against polysaccharide Ags (SPAD), CRS/ROM group: 9 SPAD, 2 XLA, 1 
dysmotile cilia syndrome, FA group: 1 patient was diagnosed as IgA deficiency. All the ASD test group children diagnosed with SPAD suffered from 
CRS/ROM.
3 Seizure disorders were reported in 4/26 (15.4%) ASD-Test and 2/107 (1.9%) ASD-control groups, respectively.
4 IgE mediated food allergy in ASD control group; all allergy to peanuts/tree nuts.
5 Frequency of CRS/ROM and PID were higher in the ASD test group (p = 0.0334 and p = 5.762e-07, respectively, by χ2 test).
6 Frequency of atopic asthma and non-atopic asthma is higher in CRS/ROM children than other study groups (p = 0.00722 and p = 8.885e-10, 
respectively, by χ2 test).
7 Control children diagnosed with asthma had either mild intermittent or mild to moderate persistent asthma and seldom required oral steroid 
burst.Journal of Neuroinflammation 2008, 5:52 http://www.jneuroinflammation.com/content/5/1/52
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2). However, CRS/ROM patients showed the highest fre-
quency of PID [mainly specific polysaccharide antibody
deficiency (SPAD)] (Table 2). More importantly, diagno-
sis of these diseases alone does not explain the frequent
infections and subsequent changes in behavioral symp-
toms in the majority of ASD test group children (Table 2).
Evaluation of innate immune responses in the test group 
ASD children
We evaluated innate immune responses by assessing
responses to TLR agonists that are important for airway
and gut mucosal immunity in the ASD test group, exclud-
ing subjects diagnosed with SPAD. Results were compared
with those obtained in ASD and normal case controls.
Demographic summaries of ASD test-group subjects and
of ASD and normal case controls are shown in Table 3.
Since the ASD test group patients were all documented to
have an initial regression, we selected ASD case controls
who also had documented initial regression. We were not
able to obtain such case controls in the FA and CRS/ROM
study groups mainly due to age-limitations.
When PBMCs were stimulated with TLR agonists without
LPS pre-treatment, PBMCs from the ASD test group
revealed lower IL-1β production with a TLR7/8 agonist
and lower IL-10 production with a TLR2/6 agonist than
did ASD control cells (Figs. 1, 2). In contrast, the ASD test
group revealed higher IL-23 production with the TLR4
agonist than control groups (Fig. 3).
Following LPS pre-treatment, the ASD test group revealed
lower IL-1β production with TLR4 and TLR7/8 agonists
(Fig. 4, 5). The ASD control group did not reveal such dif-
ferences. sTFNRII production with a TLR7/8 agonist fol-
lowing LPS pre-treatment was lower in the ASD test group
than in normal controls, and ASD controls also revealed
this tendency except for 2 outliers (Fig. 6)
Discussion
Subtle immune abnormalities in ASD children have been
reported by many researchers [13-15]. However, results
are rather variable partly due to the small number of study
subjects, heterogeneous patient populations, and lack of
careful immunological characterization of the study sub-
jects in these studies. Moreover, reported results are con-
flicting; some studies indicate type 1 T-helper (Th1)-
skewed responses while other studies indicate Th2-
skewed responses [13-16]. A high prevalence of GI symp-
toms in autistic children also raised possibilities of GI
autoimmune conditions and FA. However, to date, the
role of the immune system in the onset and progression
of ASD remains unclear.
The effects of environmental factors in genetically vulner-
able individuals have also been implicated in the develop-
ment of autism. There is ample evidence indicating that
there is increased oxidative stress in autistic children [17].
The 'redux/methylation hypothesis' postulates that envi-
ronmental factors and genetic factors play pathogenic
roles in some autistic children [17]. It has been postulated
that exposure to xenobiotics in subjects with a genetic pre-
disposition for impaired methylation and/or increased
susceptibility to oxidative stress may result in the neuro-
logical deficits observed in certain ASD children [18,19].
Oxidative stress also activates innate immunity. Interest-
ingly, the presence of low-grade chronic inflammation
has been reported in brain tissue of individuals with
autism [20,21]. This 'redux/methylation hypothesis' may
also be associated with skewed Th1 or Th2 responses in
certain conditions [22]. However, how such genetic/envi-
ronmental factors modulate the immune system in autis-
tic children is not well understood.
For a number of ASD children, parents report frequent
infections [recurrent pharyngitis and viral syndromes,
ROM, and CRS] and an unusually prolonged course of
such illnesses. Following microbial infection, parents
repeatedly describe exacerbations of behavioral symp-
toms and even loss of previously acquired cognitive skills,
an occurrence also documented by care-takers/teachers/
therapists. This study focused on this subset of ASD chil-
dren (ASD test group) as defined in the Methods section.
Our first hypothesis is that clinical features of the ASD test
group are not associated with atopy, asthma, FA, or PID.
To test this hypothesis, we retrospectively reviewed 133
ASD children referred to the Pediatric Allergy/Immunol-
ogy Clinic for evaluation of atopy/immune abnormalities.
Given the nature of our clinic, the ASD children reviewed
may have had more medical issues than ASD children in
general, as evidenced by their need to visit the clinic. Nev-
ertheless, it is advantageous to analyze these children,
since extensive data had already been generated by thor-
Table 3: Summary of matched cases
Study group Age (yr) Median (range) Atopy Asthma
ASD-test1 6.4 (3.3–11.8) 5 3
ASD-control2 6.7 (3.2–12.1) 4 3
Normal control 6.4 (3.3–12.5) 5 4
1 In ASD-test group, they are diagnosed with autism (N = 15) and 
PDD-NOS (N = 4) and the ASD case controls were matched with 
ASD diagnosis in addition to age and sex.
2 All the ASD case controls were documented to have developmental 
regression at the onset of ASD symptoms as were the ASD test 
group children.Journal of Neuroinflammation 2008, 5:52 http://www.jneuroinflammation.com/content/5/1/52
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ough allergy and immune workups. We also have the
advantage of having control non-ASD children with
chronic airway or GI inflammation who underwent a sim-
ilar workup (control CRS/ROM and FA groups) that ena-
bled us to address the presence of any distinguishing
clinical features in the ASD test group.
Prevalence of atopic disorders and asthma was equivalent
to that reported in general population in both test and
control ASD children. A lower prevalence of atopy in the
control FA patients may reflect their young age, since
atopic disorders develop with age. Likewise, a younger
median age of the control ASD children indicates that
Lower IL-1β production with a TLR7/8 agonist in the ASD test group without LPS pre-treatment Figure 1
Lower IL-1β production with a TLR7/8 agonist in the ASD test group without LPS pre-treatment. In all experi-
ments shown in Figures 1, 2, 3, 4, 5 and 6, PBMCs were incubated overnight with TLR2/6, TLR4 or TLR7/8 agonists, and 
cytokine production was examined by ELISA. The results were expressed using a boxplot: The "I" bar marks the range of TGF-
β and IL-10 levels and the thick black line marks the median. The box illustrates where the 'interquartile range' falls. 'Outliers' 
are marked separately as 'o'. IL-1β production with a TLR7/8 agonist was lower in the ASD test group than in the ASD case 
controls.
p<0.01
TLR 7/8 agonistJournal of Neuroinflammation 2008, 5:52 http://www.jneuroinflammation.com/content/5/1/52
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atopic diseases may develop with age. Nevertheless, given
the frequency of atopic disorders in the ASD test group,
who are slightly older in median age than the ASD con-
trols, it is very unlikely that atopy is associated with the
clinical features of the ASD test group.
NFA was highly prevalent in both ASD groups, consistent
with the high prevalence of GI symptoms in ASD children
(Table 2). As summarized in Table 2, a major difference in
the clinical features of the test vs. control ASD children
was the higher frequency of CRS/ROM and SPAD in the
ASD test group children. However, diagnoses of CRS/
ROM and SPAD were only seen in 6/26 and 5/26 of the
Lower IL-10 production with a TLR2/6 agonist in the ASD-test group without LPS pre-treatment Figure 2
Lower IL-10 production with a TLR2/6 agonist in the ASD-test group without LPS pre-treatment. IL-10 produc-
tion with a TLR2/6 agonist was lower in the ASD-test group than in the ASD case controls.
p<0.05 TLR 2/6 agonistJournal of Neuroinflammation 2008, 5:52 http://www.jneuroinflammation.com/content/5/1/52
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ASD test group children, respectively. All of the ASD test
group children with SPAD suffered from CRS/ROM (Table
2). SPAD was most prevalent in CRS/ROM children
(Table 2). These findings taken together suggest that the
distinguishing clinical features of the ASD test group are
unlikely to be associated with FA, asthma, or SPAD in
most of the ASD test group children.
In CRS patients, it was postulated that transmission of
inflammatory mediators via post-nasal dripping may be
associated with chronic GI irritation and predispose them
to FA [23]. It was also speculated that frequent antibiosis
and resultant dysbiosis can disrupt gut mucosal immune
homeostasis, resulting in sensitization to food proteins.
However, our results revealed a higher prevalence of NFA
Higher IL-23 production with a TLR4 agonist in the ASD test group without LPS pre-treatment Figure 3
Higher IL-23 production with a TLR4 agonist in the ASD test group without LPS pre-treatment. IL-23 produc-
tion with a TLR4 agonist was lower in the ASD test group than in the ASD and normal case controls.
p<0.01
p<0.02
TLR4 agonistJournal of Neuroinflammation 2008, 5:52 http://www.jneuroinflammation.com/content/5/1/52
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in ASD children than in CRS/ROM children, who were
likely to have had more frequent antibiosis than ASD chil-
dren (Tables 2). Asthma was prevalent in CRS/ROM chil-
dren, which is not surprising since CRS is one of the major
triggers of asthma [12]. Our findings indicate CRS/ROM
children do not display clinical features similar to those
observed in ASD test or ASD control children, making it
unlikely that CRS/ROM account for the high prevalence of
NFA in ASD children in our study.
Lower IL-1β production with a TLR4 agonist in the ASD test group following LPS pre-treatment Figure 4
Lower IL-1β production with a TLR4 agonist in the ASD test group following LPS pre-treatment. In experiments 
shown in Figures 4, 5 and 6, PBMCs were treated with LPS (0.1 μg/ml) overnight and re-stimulated with TLR agonists as 
described in Figure 1 after replacing the culture medium. IL-1β production was lower in the ASD test group in this setting than 
in the normal case controls.
p<0.005
TLR4 agonist following LPS pre-treatmentJournal of Neuroinflammation 2008, 5:52 http://www.jneuroinflammation.com/content/5/1/52
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It is of note that we did not find a high prevalence of
known PID in control ASD children, although the test
group ASD children revealed a few cases of SPAD (Table
2). Therefore, extensive immune workup focusing on PID
is likely to yield negative results in most ASD children,
especially those without concerning clinical features, as
reported previously [24].
In summary, our results support our initial hypothesis
that the distinct clinical features of our ASD test group are
not associated with atopy, asthma, FA, or presence of
known PID. However, our results have limitations. The
number of the subjects and a potentially skewed popula-
tion due to the fact that the ASD study subjects were those
evaluated in the Pediatric Allergy/Immunology Clinic
have some bearing on our results. A larger population
Lower IL-1β production with a TLR7/8 agonist in the ASD test group following LPS pre-treatment Figure 5
Lower IL-1β production with a TLR7/8 agonist in the ASD test group following LPS pre-treatment. IL-1β pro-
duction was lower in the ASD test group following LPS pre-treatment in the ASD test group than in the normal case controls.
p<0.02
TLR7/8 agonist following LPS pre-treatmentJournal of Neuroinflammation 2008, 5:52 http://www.jneuroinflammation.com/content/5/1/52
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study will be informative to further elaborate our initial
findings.
In this study, we identified 19 ASD test group children
without SPAD among 133 ASD children (14.3%). Patho-
gens affecting these ASD test group children appeared var-
ious, indicating the possibility of impaired antigen-
independent immune responses – innate immunity.
Innate immunity mounts the first line, antigen-independ-
ent immune defense by recognizing microbial by-prod-
ucts or those from damaged tissue cells via pattern
recognition receptors including TLRs [25-27]. TLR-medi-
ated responses lead to the production of various soluble
mediators that can signal the brain [28-31]. Such signal-
Lower sTNFRII production with a TLR7/8 agonist in the ASD test group following LPS pre-treatment Figure 6
Lower sTNFRII production with a TLR7/8 agonist in the ASD test group following LPS pre-treatment. sTNFRII 
production with a TLR7/8 agonist was lower in the ASD test group than in normal case controls.
p<0.02
TLR7/8 agonist following LPS pre-treatment Journal of Neuroinflammation 2008, 5:52 http://www.jneuroinflammation.com/content/5/1/52
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ling events help the central nervous system restore auto-
nomic homeostasis and provide inhibitory regulatory
signals to prevent excessive immune responses [28]. Sub-
tle changes in innate immune responses can affect the
intricate neuro-immune network that is mediated by
innate immunity. Since NFA prevalence was similar in
both the ASD groups, it was the frequent occurrence of
viral syndromes in the ASD test group children that led us
to our 2nd hypothesis. Namely, we theorized that TLR
responses, especially those sensing viral by-products, are
altered in the ASD test group.
Among TLRs, TLR2 is important for sensing encapsulated
bacteria and intracellular pathogens such as mycobacte-
rium [32,33]. TLR4 is important for sensing gram negative
bacteria, common found in the GI tract [32]. TLR7/8 are
important for sensing single stranded RNA derived from
RNA viruses, which are common causes of childhood viral
infections including measles, rhinovirus (the most com-
mon cause of 'cold'), and influenza [34]. This study
assessed responses to TLR2/6, 4, and 7/8 agonists by
measuring production of a panel of cytokines in the test
group ASD children without SPAD and comparing those
to children with ASD and to normal case controls. It is
important to mention that since many FA patients out-
grow this condition with age, the FA control children are
younger than the ASD children evaluated in the study. In
addition, the number of non-ASD controls with FA or
CRS/ROM is low due to the fact that the study was limited
to patients evaluated/treated in our clinic. Thus the study
is lacking non-ASD case controls with FA or CRS/ROM for
evaluation of innate immune responses.
Several abnormalities were found in the ASD test group:
lower production of IL-6 with the TLR2/6 agonist, lower
production of IL-1β with the TLR7/8 agonist, and higher
production of IL-23 with the TLR4 agonists than case con-
trols in the absence of LPS pre-treatment. These cytokines
which were found to be altered in production in the ASD
test group are the key regulators in the neuro-immune net-
work [28,35,36]. Thus our findings indicate that children
in the ASD test group may be less capable of controlling
microbial infection in the initial stages, leading to ineffec-
tive signalling to the brain. It is also intriguing to find
increased production of IL-23 with the TLR4 agonist in the
ASD test, since IL-23 is associated with development and
maintenance of Th17 cells, a recently defined T-helper cell
subset [37,38]. It is of note that Th17 cells are implicated
in various autoimmune and chronic inflammatory dis-
eases including multiple sclerosis and inflammatory
bowel diseases [37-39]. Thus the ASD test group children
may be more prone to Th17-mediated inflammatory
responses.
When immune cells were pre-treated with LPS, a TLR4
agonist, subsequent TLR responses were suppressed; this
phenomenon is called LPS tolerance [40]. This is thought
to be important for immune homeostasis in the gut, and
especially in the colon where bacteria exist at high density
and hence innate immune cells in the mucosa are likely to
have frequent exposures to endotoxins (LPS) [40]. We
found lower IL-1β production by PBMCs with TLR4 or
TLR7/8 agonists following LPS pre-treatment in the ASD
test group. IL-1β is one of the major mediators of the
neuro-immune network for maintenance of homeostasis
[35,36,41]. Thus suboptimal production of IL-1β may
impair neuro-immune signaling, while excessive IL-1β
can be toxic to the brain [35,41,42]. Our finding may indi-
cate a risk of suboptimal neuro-immune signalling in the
ASD test group.
sTNFRII is an important counter-regulatory cytokine for
TNF-α as made evident by the marked therapeutic effects
of exogenous sTNFRII in the treatment of certain autoim-
mune diseases [43]. We also found lower sTNFRII produc-
tion by PBMCs with TLR 7/8 agonist following LPS pre-
treatment in the ASD test group, indicating a possibility of
blunted counter-regulatory measures in the ASD test
group at the time of viral infection. However, sTNFRII
production in this condition also appeared to be lower in
the ASD control group except for 2 high outliers. Thus this
finding may not be specific for the ASD test group chil-
dren.
Taken together, our findings of altered TLR7/8 responses
with or without endotoxin (LPS) pre-treatment may indi-
cate a predisposition to recurrent viral infections in the
ASD test group as compared to ASD and non-ASD case
controls. The above-described, altered TLR responses may
also affect neuro-immune interactions in the test group.
Our findings may be useful further defining this subset of
ASD children in larger scale studies.
Conclusion
Our results indicate the presence of a distinct subset of
ASD children. This subset, the ASD-test group, is charac-
terized by frequent infections and by recurrent loss of pre-
viously acquired cognitive skills with worsening
behavioral symptoms following infection. Clinical fea-
tures of this subset were not associated with atopy,
asthma, FA, or PID in this study but may be associated
with altered TLR responses important for neuro-immune
interactions.
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